Directions of Epidemiological Surveillance of Chronic Lung Infections Caused by Burkholderia cepacia Complex, Achromobacter spp., Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus in Patients with Cystic Fibrosis

Relevance. The absence of a system of epidemiological surveillance of chronic lung infection (CLI) in patients with cystic fibrosis (CF) led to the spread of Staphylococcus aureus, Pseudomonas aeruginosa, Burkholderia cepacia complex and Achromobacter spp. among patients with CF during hospitalizations, that is proved by numerous cases of infection in patients with CF treated in various Russian clinics.

Aims. Determine the directions of epidemiological surveillance (ES) for CLI in patients with CF and preventive measures necessary to counteract the cross-infections among patients with CF and the spread of the dominant pathogens of CLI in the hospital.

Materials and methods. A complex of epidemiological, microbiological and molecular genetic methods was used.

Results and discussion. Based on the results of studies of the epidemiological and microbiological features of infections caused by the above-mentioned pathogens, the directions of ES and preventive measures for CF were determined. The tasks of the information-analytical unit, including the monitoring of morbidity and microbiological monitoring, are substantiated. It has been established that in the framework of microbiological monitoring, it is necessary to conduct bacteriological examination of biomaterial from the respiratory tract of patients with CF not less than 1 time per quarter, as well as at each outpatient visit and at hospitalization. The necessity of studying the phenotypic properties of pathogens contributing to long-term persistence in the patient's body of the CF, the definition and monitoring of the antibiotic sensitivity of microorganisms isolated from the patient over time, and the study of hypermutability was shown. One of the main tasks of monitoring is molecular genetic analysis of pathogens by PCR for the purpose of intraspecies identification, typing of pathogens and detection of epidemic markers and clones (including international ones), identification of genetic determinants of antibiotic resistance.

Conclusion. The introduction of ES for chronic lung infection will improve the quality of etiological diagnosis, will contribute early identification of the sources of infections and prevent the spread of CLI pathogens among patients with CF in hospitals and in non-hospital conditions, as well as optimize the tactics of CLI antimicrobial therapy. The main directions of preventing the spread of CLI pathogens should be the separation of patients with various infections during outpatient examination and isolation during hospitalization.

1. Chernukha M Yu, Shaginyan IA. M icrobiology of chronic lung infection in patients with cystic fibrosis. In book Cystic Fibrosis (Mucoviscidosis). MEDPRACTIKA-M, 2014; Chapter 4.2:116-48 (In Russ.).

2. Avetisyan LR, Chernukha MYu, Shaginyan IA et al. Antibiotics sensitivity of Staphylococcus aureus, Pseudomonas aeruginosa and Burkholderia cepacia complex, persisting in lungs of patients with in cystic fibrosis. Journal of microbiology epidemiology and immunobiology. 2015; 6:3-10 (In Russ.).

3. Pokrovsky VI, Pak SG, Briko Ni et al. Infectious Diseases and Epidemiology: A Textbook for High Schools., V. 2. Moscow: GEOtAr Media. 2007:816 (In Russ.).

4. Shaginyan IA, Chernukha MY, Avetisyan LR et al. Epidemiological Features of Chronic Lung Infection in Patients with Cystic Fibrosis. Epidemiology and Vaccinal Prevention. 2017;16 (6): 5-13 (In Russ.).

5. Chernukha MY, Avetisyan LR, Shaginyan IA et al. Phenotypic and genotypic characteristics of strains of the bacterium Burkholderia cepacia complex isolated from cystic fibrosis patients. Pediatrija. 2014; 93 (4): 24-31 (In Russ.).

6. Krasovskiy SA, Amelina El, Kondrat'eva EI et al. Lower respiratory infection in patients with cystic fibrosis in Russian Federation according to the National Register, 2014. Russian Pulmonology. 2016; 26 (4): 421-435 (In Russ.).

7. Kondratieva EI, Krasovskiy SA, Voronkova AYu et al. The Russian Federation Cystic Fibrosis Patient Registry for 2017, ed. Moscow: «MEDPRACTICA-M». 2016:72 (In Russ.).

8. Bittar F, Richet H, Dubus JC et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS ONE. 2008; 3 (8): e2908. doi: 10.1371/journal.pone.0002908.

9. Kahl B, Herrmann M, Everding AS et al. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis. 1998; 177: 1023-1029. DOI: 10.1086/515238.

10. Miller MB, Gilligan PH. Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol. 2003, Vol.41, P.4009-4015. DOI: 10.1128/jcm.41.9.4009-4015.2003.

11. Kidd TJ, Ramsay KA, Hu H et al. Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients. J Clin Microbiol. 2009; 47: 1503-1509. DOI: 10.1128/JCM.00014-09.

12. Chernukha MYu, Avetisyan LR, Shaginyan IA et al. Microbiological Diagnosis Algorithm for Chronic Lung Infection in Patients with Cystic Fibrosis. Journal of clinical microbiology and antimicrobial chemotherapy. 2014; 16 (4): 312-324. (in Russ).

13. Humphreys H, Peckham D, Patel P et al. Airborne dissemination of Burkholderia (Pseudomonas) cepacia from adult patients with cystic fibrosis. Thorax. 1994;.49:1157. doi: 10.1136/thx.49.11.1157.